EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Yoshiya Tanaka, Satoshi Soen, Shintaro Hirata, Yosuke Okada, Saeko Fujiwara, Ikuko Tanaka, Yuriko Kitajima, Takuo Kubota, Kosuke Ebina, Yuichi Takashi, Reiko Inoue, Mika Yamauchi und 9 weitere

Journal of Bone and Mineral Metabolism · 2024-03 · 42 (2) · 143-154

DOI: 10.1007/s00774-024-01502-w ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 28.03.2024. Verfasst von Yoshiya Tanaka und 20 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-Nish…. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Fractures, Bone. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Society for Bone and Mineral Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30–50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months. Materials and methods The Committee on the revision of the guidelines for the management and treatment of GIOP of the JSBMR prepared 17 clinical questions (CQs) according to the GRADE approach and revised the guidelines for the management and treatment of GIOP through systematic reviews and consensus conferences using the Delphi method.

Results

Bisphosphonates (oral and injectable formulations), anti-RANKL antibody teriparatide, eldecalcitol, or selective estrogen receptor modulators are recommended for patients who has received or scheduled for GC therapy with risk factor scores of ≥3. It is recommended that osteoporosis medication is started concomitantly with the GC therapy for the prevention of fragility fractures in elderly patients.

Conclusion

The 2023 guidelines for the management and treatment of GIOP was developed through systematic reviews and consensus conferences using the Delphi method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosisFractures, BoneAgedHumansAdolescentAdultInfantGlucocorticoidsQuality of LifeBone Density

Stichwörter der Autor:innen

FractureGlucocorticoidGlucocorticoid-induced osteoporosisOsteoporosisTreatment

Substanzen

GlucocorticoidsBone Density Conservation Agents

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-Nishi, Kitakyushu, 807-8555, Japan. tanaka@med.uoeh-u.ac.jp.
  • Soen Orthopaedics, Osteoporosis and Rheumatology Clinic, Kobe, Japan.
  • Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
  • Clinical Research Center, Hospital of the University of Occupational and Environmental Health, Kyoto, Japan.
  • Department of Pharmacy, Yasuda Women's University, Hiroshima, Japan.
  • Initiative for Rheumatology & Osteoporosis, Nagoya Rheumatology Clinic, Nagoya, Japan.

Förderung

  • Japanese Society for Bone and Mineral Research

Zitieren

APA

Tanaka, Y., Soen, S., Hirata, S., Okada, Y., Fujiwara, S., Tanaka, I., Kitajima, Y., Kubota, T., Ebina, K., Takashi, Y., Inoue, R., Yamauchi, M., Okubo, N., Ueno, M., Ohata, Y., Ito, N., Ozono, K., Nakayama, H., Terauchi, M., …, & Fukumoto, S. (2024). The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. Journal of Bone and Mineral Metabolism, 42(2), 143-154. https://doi.org/10.1007/s00774-024-01502-w

Vancouver

Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, et al. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. Journal of Bone and Mineral Metabolism. 2024;42(2):143-154. doi:10.1007/s00774-024-01502-w

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Yoshiya and Soen, Satoshi and Hirata, Shintaro and Okada, Yosuke and Fujiwara, Saeko and Tanaka, Ikuko and Kitajima, Yuriko and Kubota, Takuo and Ebina, Kosuke and Takashi, Yuichi and Inoue, Reiko and Yamauchi, Mika and Okubo, Naoaki and Ueno, Masanobu and Ohata, Yasuhisa and Ito, Nobuaki and Ozono, Keiichi and Nakayama, Hisanori and Terauchi, Masakazu and Tanaka, Sakae and Fukumoto, Seiji},
  title = {The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2024},
  volume = {42},
  number = {2},
  pages = {143--154},
  doi = {10.1007/s00774-024-01502-w}
}
Kostenlos starten →